GFAP and Alzheimer disease: Studies confirmed that plasma GFAP is a stable (~ 7 days at room temperature) and effective biomarker for detecting AD, particularly in more advanced stages (MMSE < 20), and could reliably distinguish AD patients from the HC [55].